{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:50:41Z","timestamp":1782384641382,"version":"3.54.5"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG018440"],"award-info":[{"award-number":["AG018440"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG073979"],"award-info":[{"award-number":["AG073979"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS047101"],"award-info":[{"award-number":["NS047101"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dmd.2026.100304","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:14:27Z","timestamp":1776467667000},"page":"100304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peptide-mediated delivery of an \u03b1-synuclein\u2013targeting antisense oligonucleotide: Pharmacokinetics, safety, and central nervous system efficacy in a synucleinopathy model"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1387-1943","authenticated-orcid":false,"given":"Rijwan U.","family":"Ahammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2968-8077","authenticated-orcid":false,"given":"Sahar","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9245-8278","authenticated-orcid":false,"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-1941","authenticated-orcid":false,"given":"Brian","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2026.100304_bib1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson's disease mouse model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"10.1016\/j.dmd.2026.100304_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135633","article-title":"\u03b1-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson\u2019s disease","volume":"6","author":"Cole","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.dmd.2026.100304_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100304_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2'-O-methoxyethyl\u2013modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100304_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100304_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jgm.838","article-title":"Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide","volume":"8","author":"Fletcher","year":"2006","journal-title":"J Gene Med"},{"key":"10.1016\/j.dmd.2026.100304_bib7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.omtm.2020.04.012","article-title":"Translational feasibility of lumbar puncture for intrathecal AAV administration","volume":"17","author":"Hinderer","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"18","key":"10.1016\/j.dmd.2026.100304_bib8","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"7367","key":"10.1016\/j.dmd.2026.100304_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.dmd.2026.100304_bib10","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"10.1016\/j.dmd.2026.100304_bib11","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1002\/anie.201914751","article-title":"Systemic brain delivery of antisense oligonucleotides across the blood-brain barrier with a glucose-coated polymeric nanocarrier","volume":"59","author":"Min","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"issue":"7014","key":"10.1016\/j.dmd.2026.100304_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.dmd.2026.100304_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nbd.2019.03.001","article-title":"Systemic peptide mediated delivery of an siRNA targeting \u03b1-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease","volume":"127","author":"Spencer","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.dmd.2026.100304_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106285","article-title":"Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce \u03b1-synuclein in a mouse model of Alzheimer's disease","volume":"186","author":"Leit\u00e3o","year":"2023","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.dmd.2026.100304_bib15","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009399","article-title":"\u03b1-Synuclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10423","key":"10.1016\/j.dmd.2026.100304_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.dmd.2026.100304_bib17","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100304_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13311-019-00714-7","article-title":"Nucleic acid-based therapeutics for Parkinson's disease","volume":"16","author":"Nakamori","year":"2019","journal-title":"Neurotherapeutics"},{"issue":"5456","key":"10.1016\/j.dmd.2026.100304_bib19","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in \u03b1-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.dmd.2026.100304_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1749-6632.2003.tb07475.x","article-title":"Transgenic models of \u03b1-synuclein pathology: past, present, and future","volume":"991","author":"Hashimoto","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100304_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016575","article-title":"Peripheral delivery of a CNS targeted, metalo-protease reduces A\u03b2 toxicity in a mouse model of Alzheimer\u2019s disease","volume":"6","author":"Spencer","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.dmd.2026.100304_bib22","first-page":"331","article-title":"Applications of ApoB LDLR-binding domain approach for the development of CNS-penetrating peptides for Alzheimer\u2019s disease","volume":"1324","author":"Masliah","year":"2015"},{"key":"10.1016\/j.dmd.2026.100304_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-015-0043-6","article-title":"A brain-targeted, modified neurosin (kallikrein-6) reduces \u03b1-synuclein accumulation in a mouse model of multiple system atrophy","volume":"10","author":"Spencer","year":"2015","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.dmd.2026.100304_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106397","article-title":"Corrigendum to \"Systemic peptide mediated delivery of an siRNA targeting \u03b1-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy Body Disease\" [Neurobiology of Disease127 (2019) 163\u2013177]","volume":"191","author":"Spencer","year":"2024","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.dmd.2026.100304_bib25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.106.012401","article-title":"Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"1-2","key":"10.1016\/j.dmd.2026.100304_bib26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0022-1759(89)90104-X","article-title":"Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays","volume":"125","author":"Bobrow","year":"1989","journal-title":"J Immunol Methods"},{"issue":"3","key":"10.1016\/j.dmd.2026.100304_bib27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"10.1016\/j.dmd.2026.100304_bib28","first-page":"71","article-title":"An improvement of the 2^(\u2013delta delta CT) method for quantitative real-time polymerase chain reaction data analysis","volume":"3","author":"Rao","year":"2013","journal-title":"Biostat Bioinforma Biomath"},{"issue":"6","key":"10.1016\/j.dmd.2026.100304_bib29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.dmd.2026.100304_bib30","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jnr.10231","article-title":"Differential neuropathological alterations in transgenic mice expressing \u03b1-synuclein from the platelet-derived growth factor and Thy-1 promoters","volume":"68","author":"Rockenstein","year":"2002","journal-title":"J Neurosci Res"},{"issue":"4","key":"10.1016\/j.dmd.2026.100304_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10611860290031877","article-title":"Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier","volume":"10","author":"Kreuter","year":"2002","journal-title":"J Drug Target"},{"issue":"19","key":"10.1016\/j.dmd.2026.100304_bib32","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3390\/cells12192395","article-title":"Enhancing antisense oligonucleotide-based therapeutic delivery with DG9, a versatile cell-penetrating peptide","volume":"12","author":"Haque","year":"2023","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.dmd.2026.100304_bib33","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.3390\/ijms25073995","article-title":"Neuroinflammation in neurodegenerative disorders: current knowledge and therapeutic implications","volume":"25","author":"Giri","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"25","key":"10.1016\/j.dmd.2026.100304_bib34","doi-asserted-by":"crossref","first-page":"17917","DOI":"10.1074\/jbc.M114.557439","article-title":"A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis","volume":"289","author":"Spencer","year":"2014","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100304_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbamem.2016.10.019","article-title":"Identification of a novel lipid binding motif in apolipoprotein B by the analysis of hydrophobic cluster domains","volume":"1859","author":"Gordon","year":"2017","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"28","key":"10.1016\/j.dmd.2026.100304_bib36","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.1523\/JNEUROSCI.4787-13.2014","article-title":"Synucleins regulate the kinetics of synaptic vesicle endocytosis","volume":"34","author":"Vargas","year":"2014","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100304_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","article-title":"\u03b1-Synuclein in synaptic function and dysfunction","volume":"46","author":"Sharma","year":"2023","journal-title":"Trends Neurosci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100304_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","article-title":"Increased expression of \u03b1-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis","volume":"65","author":"Nemani","year":"2010","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.dmd.2026.100304_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener Dis"},{"issue":"20","key":"10.1016\/j.dmd.2026.100304_bib40","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1523\/JNEUROSCI.22-20-08797.2002","article-title":"Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking \u03b1-synuclein","volume":"22","author":"Cabin","year":"2002","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100304_bib41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","article-title":"Mice lacking \u03b1-synuclein display functional deficits in the nigrostriatal dopamine system","volume":"25","author":"Abeliovich","year":"2000","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.dmd.2026.100304_bib42","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.neurobiolaging.2008.11.001","article-title":"Absence of \u03b1-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice","volume":"31","author":"Al-Wandi","year":"2010","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.dmd.2026.100304_bib43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12974-016-0694-4","article-title":"\u03b1-Synuclein deficiency promotes neuroinflammation by increasing Th1 cell-mediated immune responses","volume":"13","author":"Ettle","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"5646","key":"10.1016\/j.dmd.2026.100304_bib44","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"\u03b1-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.dmd.2026.100304_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311022","article-title":"Are therapies that target \u03b1-synuclein effective at halting Parkinson's disease progression? A systematic review","volume":"24","author":"Rodger","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2026.100304_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.dmd.2026.100304_bib47","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3233\/JAD-131883","article-title":"Central and peripheral administration of antisense oligonucleotide targeting amyloid-\u03b2 protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (A\u03b2PPswe) mice","volume":"40","author":"Farr","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.dmd.2026.100304_bib48","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3233\/JAD-2011-111517","article-title":"Peripheral administration of antisense oligonucleotides targeting the amyloid-\u03b2 protein precursor reverses A\u03b2PP and LRP-1 overexpression in the aged SAMP8 mouse brain","volume":"28","author":"Erickson","year":"2012","journal-title":"J Alzheimers Dis"},{"issue":"760","key":"10.1016\/j.dmd.2026.100304_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2245","article-title":"Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier","volume":"16","author":"Barker","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.dmd.2026.100304_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1584190","article-title":"Editorial: The potential of transferrin as a drug target and drug delivery system","volume":"16","author":"Carrilho","year":"2025","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100304_bib51","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1083\/jcb.138.4.877","article-title":"A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier","volume":"138","author":"Dehouck","year":"1997","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100304_bib52","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1194\/jlr.R300017-JLR200","article-title":"Functions of lipoprotein receptors in neurons","volume":"45","author":"Beffert","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.dmd.2026.100304_bib53","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.dmd.2026.100304_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","article-title":"Targeting RNA-mediated toxicity in C9orf72 ALS and\/or FTD by RNAi-based gene therapy","volume":"16","author":"Martier","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.dmd.2026.100304_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100304_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12987-025-00643-y","article-title":"The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo","volume":"22","author":"Bonvicini","year":"2025","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"10.1016\/j.dmd.2026.100304_bib57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40262-014-0224-4","article-title":"Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro\u00ae): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B","volume":"54","author":"Geary","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmd.2026.100304_bib58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmd.2026.100304_bib59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:23:25Z","timestamp":1782383005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0090955626000735"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100304","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide-mediated delivery of an \u03b1-synuclein\u2013targeting antisense oligonucleotide: Pharmacokinetics, safety, and central nervous system efficacy in a synucleinopathy model","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100304"}}